Role of CCL18 in asthma and lung immunity
Article first published online: 21 JUN 2013
© 2012 John Wiley & Sons Ltd
Clinical & Experimental Allergy
Volume 43, Issue 7, pages 716–722, July 2013
How to Cite
Clinical & Experimental Allergy 2013; (43) 716–722, , , , .
- Issue published online: 21 JUN 2013
- Article first published online: 21 JUN 2013
- Accepted manuscript online: 26 NOV 2012 04:43AM EST
- Manuscript Accepted: 1 NOV 2012
- Manuscript Revised: 29 OCT 2012
- Manuscript Received: 18 SEP 2012
Allergic asthma is a prototypic Th2 mediated disease, where chemokines orchestrate the inflammatory cell recruitment. Most chemokines have a pro-inflammatory role. In this review, we focus on the potential role, in asthma and lung immunity, of CCL18 a chemokine both constitutively expressed at high levels in the lung and induced in inflammatory conditions. This chemokine is mainly produced by antigen presenting cells, and induced by Th2 type cytokines. The available data suggest that this chemokine may exhibit dual functions, with both pro- and anti-inflammatory properties, the latter through its ability to generate adaptive regulatory T cells in healthy subjects, with a loss of function in allergic patients. However, the functional implications are at the moment hampered by the lack of data on the nature of its putative receptor, and the absence of murine orthologue.